



# In Vitro Skin Permeation and Antifungal Activity of Naftifine Microemulsions

## Naftifin Mikroemülsiyonlarının In Vitro Deriden Permeasyonu ve Antifungal Aktivitesi

✉ Meryem Sedef ERDAL<sup>1\*</sup>, Dr. Aslı GÜRBÜZ<sup>1</sup>, Dr. Seher BİRTEKSÖZ TAN<sup>2</sup>, Dr. Sevgi GÜNGÖR<sup>1</sup>, Dr. Yıldız ÖZSOY<sup>1</sup>

<sup>1</sup>İstanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, Turkey

<sup>2</sup>İstanbul University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, İstanbul, Turkey

### ABSTRACT

**Objectives:** Microemulsions are fluid, isotropic, colloidal systems that have been widely studied as drug delivery systems. The percutaneous transport of active agents can be enhanced by their microemulsion formulation when compared to conventional formulations. The purpose of this study was to evaluate naftifine-loaded microemulsions with the objective of improving the skin permeation of the drug.

**Materials and Methods:** Microemulsions comprising oleic acid (oil phase), Kolliphor EL or Kolliphor RH40 (surfactant), Transcutol (co-surfactant), and water were prepared and physicochemical characterization was performed. *In vitro* skin permeation of naftifine from microemulsions was investigated and compared with that of its conventional commercial formulation. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy was used to evaluate the interaction between the microemulsions and the stratum corneum lipids. *Candida albicans* American Type Culture Collection (ATCC) 10231 and *Candida parapsilosis* were used to evaluate the antifungal susceptibility of the naftifine-loaded microemulsions.

**Results:** The microemulsion formulation containing Kolliphor RH40 as co-surfactant increased naftifine permeation through pig skin significantly when compared with the commercial topical formulation ( $p<0.05$ ). ATR-FTIR spectroscopy showed that microemulsions increased the fluidity of the stratum corneum lipid bilayers. Drug-loaded microemulsions possessed superior antifungal activity against *Candida albicans* ATCC 10231 and *Candida parapsilosis*.

**Conclusion:** This study demonstrated that microemulsions could be suggested as an alternative topical carrier with potential for enhanced skin delivery of naftifine.

**Key words:** Naftifine, microemulsion, colloidal drug carrier system, topical antifungal

### ÖZ

**Amaç:** Mikroemülsiyonlar, ilaç taşıyıcı sistemler olarak çok çalışılan; sıvı, izotropik, kolloidal sistemlerdir. Aktif maddelerin mikroemülsiyonlardan perktütan absorpsiyonu konvansiyonel formülasyona göre iyileşebilmektedir. Bu çalışmanın amacı, naftifin yüklü mikroemülsiyonların, ilacı deriden permeasyonunun iyileştirilmesine yönelik olarak değerlendirilmesidir.

**Gereç ve Yöntemler:** Oleik asit (yağ fazı), Kolliphor EL veya Kolliphor RH40 (surfaktan), Transcutol (ko-surfaktan) ve sudan oluşan mikroemülsiyonlar hazırlanarak fizikokimyasal karakterizasyonları gerçekleştirilmiştir. Naftifinin *in vitro* deriden permeasyonu çalışılmış ve konvansiyonel ticari preparatı ile karşılaştırılmıştır. Zayıflatılmış toplam yansımış-Fourier dönüşümü (ATR-FTIR) spektroskopisi, mikroemülsiyonlar ile stratum corneum lipitleri arasındaki etkileşimin araştırılması için kullanılmıştır. Naftifin yüklü mikroemülsiyonların antifungal aktiviteleri *Candida albicans* Amerikan Tip Kültür Koleksiyonu (ATCC) 10231 ve *Candida parapsilosis* kullanılarak değerlendirilmiştir.

**Bulgular:** Ko-surfaktan olarak Kolliphor RH40 içeren mikroemülsyon formülasyonu, naftifinin topikal ticari formülasyonu ile karşılaştırıldığında, domuz derisinden naftifin permeasyonunu istatistiksel olarak anlamlı derecede arttırmıştır ( $p<0,05$ ). ATR-FTIR spektroskopisi, mikroemülsiyonların stratum corneum lipit çift tabakalarının akışkanlığını artırdığını göstermiştir. İlaç yüklü mikromülsiyonlar, *Candida albicans* ATCC 10231 ve *Candida parapsilosis* türlerine karşı yüksek antifungal aktivite göstermişlerdir.

**Sonuç:** Sonuç olarak, bu çalışmada mikroemülsiyonların, naftifinin deriden permeasyonunun iyileştirilmesinde alternatif topikal taşıyıcılar olarak kabul edilebilecekleri gösterilmiştir.

**Anahtar kelimeler:** Naftifin, mikroemülsyon, kolloidal ilaç taşıyıcı sistem, topikal antifungal

\*Correspondence: E-mail: serdal@istanbul.edu.tr, Phone: +90 532 302 16 16 ORCID-ID: orcid.org/0000-0001-6220-2036

Received: 13.07.2018, Accepted: 18.10.2018

©Turk J Pharm Sci, Published by Galenos Publishing House.

## INTRODUCTION

Naftifine hydrochloride (naftifine) is a synthetic, topical allylamine antifungal compound that is effective in the management of superficial dermatomycoses. Naftifine shows primarily fungicidal activity against *Candida* species including *Candida albicans* (*C. albicans*) and *Candida parapsilosis* (*C. parapsilosis*) and it has been proven to be especially effective in moderate to severe cutaneous candidiasis caused by these two species.<sup>1,2</sup>

The strongly lipophilic nature of naftifine ( $\log p: 5.4$ ) leads to its accumulation in high concentrations within the stratum corneum, which is the outermost barrier layer of the skin. However, the therapeutic efficacy of antifungal drugs applied topically depends on the ability of the formulation to overcome the stratum corneum barrier and improve the uptake in deeper skin layers.<sup>3</sup> Therefore, a drug delivery system aiming to increase the topical penetration of naftifine is important to enhance its local antifungal efficacy. Microemulsions are colloidal nano-sized carriers with a dynamic microstructure that form spontaneously by combining appropriate amounts of oil, water, surfactant, and a co-surfactant.<sup>4,5</sup> They are thermodynamically stable and isotropic systems and they have been extensively explored for a variety of pharmaceutical applications, including dermal and transdermal drug delivery.<sup>6-9</sup> The high solubilization capacity of microemulsions and their ability to modify the diffusional barrier of the stratum corneum can facilitate drug penetration into deeper skin layers compared to conventional formulations.<sup>10,11</sup> The aim of the present study was to formulate and evaluate the *in vitro* skin permeation and antifungal activity of naftifine-loaded microemulsion formulations comprising oleic acid (oil phase), Kolliphor EL or Kolliphor RH40 (surfactant), Transcutol (co-surfactant), and water. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy was used to evaluate the interaction between the microemulsions and the stratum corneum lipids. The antifungal susceptibility of naftifine-loaded microemulsions was assessed against two *Candida* species, namely *C. albicans* American Type Culture Collection (ATCC) 10231 and *C. parapsilosis*.

## MATERIALS AND METHODS

### Materials

Naftifine was kindly provided by Eczacıbaşı Drug Company (İstanbul, Turkey), and the polyoxyl castor oils (Kolliphor® EL and Kolliphor® RH40) were kind gifts from BASF (Limburgerhof, Germany). Oleic acid was purchased from Sigma (St. Louis, MO, USA). Diethylene glycol monoethyl ether (Transcutol P®) was kindly provided by Gattefossé (Lyon, France). RPMI-1640 medium and 4-morpholinepropanesulfonic acid (MOPS) were purchased from Sigma (St. Louis, MO, USA). All other chemicals used in the study were of analytical grade.

### Preparation and characterization of microemulsions

We previously reported the preparation and physicochemical characterization of microemulsions loaded with naftifine.<sup>12</sup> Briefly, the concentration range of components necessary

for the formation of microemulsions was determined by construction of pseudoternary phase diagrams based on water titration at ambient temperature ( $25\pm0.5^\circ\text{C}$ ). The oil phase to surfactant/cosurfactant mixture ratio varied from 1:9 to 9:1 (w/w) and the ratio of surfactant/co-surfactant (km) was fixed as 1:2. The microemulsions were formed spontaneously at room temperature as a clear monophasic liquid (Table 1). Naftifine was solubilized in the oil phase at 1% concentration before preparation of the microemulsions. In order to verify the isotropic nature of the optimized microemulsions ME1 and ME2, cross-polarized light microscopy (Olympus BX51 U-AN 360, Tokyo, Japan) imaging was performed. The droplet size and the polydispersity index of the microemulsions were determined using dynamic light scattering (Malvern Zetasizer Nano ZS, Malvern Instruments, Malvern, Worcestershire, UK) after pre-filtering (0.45 mm, Millex) of the microemulsions. The electric conductivity and pH of the microemulsions were measured using a combined device (Eutech PC 700; Eutech Instruments, Landsmeer, the Netherlands) at room temperature. The refractive index of the microemulsions was determined by a digital Abbe Refractometer (Atogo Co. Ltd., Tokyo, Japan). In order to measure the viscosity and rheological behavior of the microemulsions a Brookfield Rheometer (Brookfield DV3THACJ0, Middleboro, MA, USA) with a cone-plate measuring device was used. All measurements were conducted in triplicate in a temperature-controlled environment at  $25^\circ\text{C}$ .

### *In vitro* permeation study

#### Preparation of skin

Pig skin (obtained from a local slaughterhouse) was carefully cleaned of fat and muscle and then dermatomed to a thickness of 750  $\mu\text{m}$  (Zimmer Electric Dermatome, Warsaw, IN, USA). The integrity of the skin was confirmed by transepidermal water loss measurement with an open chamber device (Tewameter TM 300; Courage + Khazaka Electronic, Cologne, Germany) as stated in the literature.<sup>4</sup>

#### Permeation experiments

*In vitro* permeation experiments were performed using Franz type diffusion cells (diffusion area of  $1.76\text{ cm}^2$ , Permegear V6A Stirrer, Hellertown, PA, USA). Pig skin was placed on the receiver chambers with the stratum corneum facing upwards

**Table 1. The composition of naftifine loaded microemulsion formulations**

Formulation components	ME1 (% w/w)	ME2 (% w/w)
Oleic acid	8.0	8.7
Kolliphor® RH40	19.0	-
Kolliphor® EL	-	17.2
Transcutol P®	38.0	34.8
Naftifine HCl	1.0	1.0
Water	34.0	38.1
HCl: Hydrochloride		

and then the donor chambers were clamped in place. The receptor chamber was filled with 12 mL of phosphate buffer pH 5.0 containing 30% ethanol to ensure sink conditions. The receptor phase maintained at 37°C under constant stirring (300 rpm) with a magnetic bar. Microemulsion formulation (500 µL) was placed in the donor compartments of diffusion cells. The compartments were sealed by Parafilm M® (Bemis, Oshkosh, WI, USA) immediately after the addition of the formulation in order to prevent evaporation. The permeation of naftifine from microemulsions was followed for 8 h. The commercial topical cream formulation naftifine (Exoderil) was used as the control formulation. Samples of 500 µL were removed at appropriate time intervals for analysis and replaced immediately with fresh receptor medium. The samples were analyzed for their drug content by HPLC. Permeation profiles of naftifine were constructed by plotting time (h) against the cumulative amount of the drug ( $\mu\text{g}/\text{cm}^2$ ) as measured in the receptor medium. Steady state flux ( $J_{ss}$ ,  $\text{mg}/\text{cm}^2 \cdot \text{h}$ ) was calculated from the steady state part of the curve. The effect of microemulsions as carrier on dermal administration [enhancement ratio, (ER)] is determined by the following equation:

$$\text{ER} = \text{Flux from microemulsion formulation} / \text{Flux from commercial formulation}$$

Data were determined from the average of at least six experiments.

#### *HPLC analysis*

For the HPLC (Shimadzu Model LC 20AT, Kyoto, Japan) analysis of naftifine we used a reversed phase C18 column (4.6 mm×150 mm, 5 µm, Merck, Darmstadt, Germany) preceded by a guard column (4×4 mm, 5 µm, Merck, Darmstadt, Germany). The mobile phase consisted of acetonitrile:tetrahydrofuran:tetramethyl-ammonium hydroxide buffer (pH 7.8) (62:10:28) and the flow rate was fixed at 1.2 mL/min. The wavelength of detection was set at 280 nm. The limit of quantification was found to be 0.025 µg/mL. The method was validated for selectivity, linearity, accuracy, and precision. It was found to be linear between the concentration range of 0.025–100 µg/mL with a high correlation coefficient ( $r^2=0.999$ ) and was precise (intra- and interday variation 2%) and accurate (mean recovery 99%).

#### *ATR-FTIR spectroscopy*

The effect of microemulsions ME1 and ME2 and marketed formulation (Exoderil) on pig skin was investigated by ATR-FTIR spectroscopy. For this purpose, the surface of 4 cm<sup>2</sup> pieces of dermatomed pig skin was treated with 300 µL of ME1, ME2, or commercial cream for 8 h. At the end of the treatment period ATR-FTIR spectra were recorded as the average of 40 scans with a spectral resolution of 4 cm<sup>-1</sup> in the 4000–650 cm<sup>-1</sup> range using a Perkin Elmer Spectrum 100 FTIR spectrometer (UK) equipped with a ZnSe ATR crystal. Attention was focused on characterizing the occurrence of peaks near 2850 and 2920 cm<sup>-1</sup>, which were due to the symmetric and asymmetric CH<sub>2</sub> stretching vibrations, respectively. In order to minimize intersample variation, the same piece of skin before treatment was used for normalization.<sup>13</sup>

#### *In vitro antifungal activity*

##### *Yeasts*

*C. albicans* ATCC 10231 and *C. parapsilosis* were used to evaluate the antifungal susceptibility of naftifine-loaded microemulsions. The yeasts were cultured and maintained on Sabouraud dextrose agar for 24 h at 30°C prior to testing.

##### *Assay*

The minimum inhibitory concentration (MIC) of microemulsion formulations was determined by the microdilution technique using 96-well microplates. Serial two-fold dilutions ranging from 5000 to 5 mg/mL were done following the Clinical Laboratory Standards Institute (CLSI) recommendations, rule CLSI M27-A3 for yeasts.<sup>14,15</sup> RPMI-1640 medium (Sigma, St. Louis, MO, USA) buffered to pH 7.0 with MOPS (Sigma, St. Louis, MO, USA) was used for the dilutions. The inoculum was prepared with RPMI-1640 medium, using 24 h cultures adjusted to a turbidity equivalent to a 0.5 McFarland standard, to give a final concentration of  $0.5 \times 10^3$  to  $2.5 \times 10^3$  cfu/mL in the test tray. The trays were covered and placed in plastic bags to prevent evaporation and incubated at 35°C for 46–50 h. The MICs were defined as the lowest concentration of compound giving complete inhibition of visible growth.<sup>16</sup> Naftifine was used as reference antifungal for yeast. The MIC values of the naftifine were within the accuracy range in CLSI throughout the study.<sup>14</sup> All tests were performed in triplicate.

#### *Statistical analysis*

All results are the mean ± standard deviation of at least three experiments. The statistical analysis was performed using Tukey's multiple comparison test, with p<0.05 as level of significance (GraphPad Prism 5 Software, La Jolla, CA, USA).

## RESULTS AND DISCUSSION

#### *Physicochemical characterization of microemulsions*

The small droplet size ( $7.34 \pm 0.03$ – $11.17 \pm 0.25$  nm) together with its narrow distribution ( $0.15 \pm 0.01$ – $0.19 \pm 0.01$ ) indicated the homogeneous nature of the microemulsions and explained the clarity and isotropicity of the systems. The conductivity values revealed that the microemulsions were in oil in water (o/w) form and naftifine in salt form led to increased conductivity. The pH values of the microemulsions were reasonable for their cutaneous application ( $4.26 \pm 0.01$ – $5.71 \pm 0.03$ ). The refractive indices of the microemulsions confirmed the transparency of the formulations. The apparent viscosity values of the microemulsions were  $70.76 \pm 0.12$ – $83.58 \pm 0.46$  Cp and they showed Newtonian flow behavior.<sup>12</sup>


#### *In vitro permeation study*

The permeability of naftifine from microemulsions was measured *in vitro* using excised pig skin. The cumulative percutaneous penetrating amounts of naftifine from the microemulsions and from the commercial cream are illustrated in Figure 1 and the permeation parameters are summarized in Table 2. Flux of naftifine from the microemulsion ME1 ( $109.99 \pm 1.58$   $\mu\text{g} \cdot \text{cm}^{-2} \cdot \text{h}^{-1}$ ) was significantly higher than that of ME2 ( $45.59 \pm 2.10$   $\mu\text{g} \cdot \text{cm}^{-2} \cdot \text{h}^{-1}$ )

$^2 \cdot h^{-1}$ ) and commercial cream ( $21.32 \pm 1.56 \mu\text{g} \cdot \text{cm}^{-2} \cdot h^{-1}$ ) ( $p < 0.05$ ). It has been reported that percutaneous permeation is an essential requirement for satisfactory topically applied antifungals in order to achieve therapeutic concentration for deep fungal infections.<sup>17</sup> The ability of a microemulsion to improve the transport of drugs to and across the skin is largely influenced by the composition and concentration of the microemulsion components, as well as the internal structure and type of the microemulsion used (o/w, w/o, or bicontinuous systems).<sup>10,18</sup> Various oils have been used as components of the oil phase in microemulsions. Oleic acid is one of the most frequently selected ones and it has been demonstrated that oleic acid containing microemulsions increased the penetration of lipophilic drugs through the skin.<sup>19,20</sup> Transcutol P is a well-known penetration enhancer in skin delivery and by its amphiphilic nature it has been known to reduce interfacial tension, resulting in balanced microemulsion systems.<sup>21</sup> Although both of the microemulsions contained oleic acid and Transcutol P, the highest permeation was obtained by ME1, demonstrating a possible synergistic effect of the added surfactant Kolliphor® RH40. The content of the surfactant mixture in ME1 influenced the permeation rate of naftifine. In addition, the lower viscosity of ME1 ( $75.62 \pm 0.24 \text{ cP}$ ) than ME2 ( $83.58 \pm 0.46 \text{ cP}$ ) might provide better mobility for the drug molecules and consequently a faster release with a diffusion-controlled mechanism.<sup>12,22</sup> The permeability coefficient ( $K_p$ ) of naftifine in ME1 was fivefold higher than the value obtained for the commercial formulation. The microemulsion formulation ME1 had the highest  $\text{ER}_{\text{Flux}}$  (5.16) with a ~5-fold enhancement rate compared to the commercial formulation. It was also found that the lag times were shortened when microemulsions were used (Table 2). This result was consistent with previous studies reporting that microemulsions remarkably shortened the lag time of formulations.<sup>23</sup>

#### ATR-FTIR spectroscopy

In Figure 2, the spectra of untreated pig skin (control) and pig skin treated with either microemulsion formulations (ME1 and



**Figure 1.** Comparison of skin permeation rates of naftifine from microemulsions and from the topical commercial formulation. At least 6 experiments ( $n \geq 6$ ) were performed for each formulation

ME2) or commercial cream (Exoderil) are shown. The most characteristic bands are the asymmetric and symmetric  $\text{CH}_2$  stretching absorbances at  $2920 \text{ cm}^{-1}$  and  $2850 \text{ cm}^{-1}$  arising from endogenous skin lipids. We observed that both the  $\text{CH}_2$  stretching vibration bands shifted towards higher wave numbers after microemulsion application, which could be attributed to a decrease in the conformational order of the stratum corneum lipids. Thus, disorder of the barrier might further have enhanced permeation of naftifine across the stratum corneum.<sup>17,24</sup>


#### In vitro antifungal activity of naftifine microemulsions

Naftifine is a topical antifungal agent having shown a specific inhibitory effect in sterol biosynthesis of *C. albicans* and *C. parapsilosis*.<sup>25</sup> The *in vitro* antifungal activity of naftifine-loaded microemulsions ME1 and ME2 against *C. albicans* ATCC 10231 and *C. parapsilosis* (port blood) was higher than that of the commercial topical cream (Exoderil) as can be seen in Figure 3. These results proved that microemulsions had superior fungicidal efficacies due to considerable penetration of the drug into fungal cell membranes.<sup>26</sup> Jadhav et al.<sup>27</sup> observed greater activity of fluconazole-loaded microemulsions than of conventional gel formulations and this was attributed to the better diffusion of the drug provided by the presence of surfactants and oil phase. Similarly, El-Hadidy et al.<sup>28</sup>

**Table 2.** Effect of microemulsions (ME1 and ME2) on percutaneous permeation of naftifine


Formulation	Flux ( $J_{ss}$ ) ( $\mu\text{g} \cdot \text{cm}^{-2} \cdot \text{h}^{-1}$ )	Permeability coefficient ( $K_p$ ) ( $\text{cm} \cdot \text{h}^{-1} \times 10^{-3}$ )	Lag time (h)	$\text{ER}_{\text{Flux}}$
ME1	$109.99 \pm 1.58$	$10.10 \pm 0.23$	$1.22 \pm 0.87$	5.16
ME2	$45.59 \pm 2.10$	$4.56 \pm 0.41$	$1.55 \pm 0.56$	2.14
Exoderil	$21.32 \pm 1.56$	$2.13 \pm 0.85$	$3.50 \pm 0.49$	1.00

Each data point is the mean  $\pm$  standard deviation of six determinations



**Figure 2.** Comparison of Attenuated total reflectance-Fourier transform infrared spectra of untreated and formulation (ME1, ME2, and commercial cream) treated pig skin samples

(2012) observed considerably higher antifungal activity with voriconazole microemulsions against *C. albicans* when compared to the supersaturated solution of the same drug. Microemulsion formulation M1, which contains Kolliphor EL as surfactant, showed higher antifungal activity compared to that of the microemulsion M2 and Exoderil. Kolliphor EL is a nonionic surfactant and it is a well-known formulation vehicle for various hydrophobic drugs, including anesthetics, photosensitizers, sedatives, immunosuppressive agents, and anticancer drugs.<sup>29</sup> Kolliphor EL-containing microemulsions have been considered effective topical carriers to deliver the antifungal agents oxiconazole and terconazole.<sup>30,31</sup> The composition of microemulsion M1 in our study might alter the permeation of fungal cells more than the formulation M2 and commercial cream, which consequently resulted in higher penetration of microemulsion globules containing naftifine through fungal cell walls.



**Figure 3.** Values of minimum inhibitory concentration determined either for naftifine-containing microemulsions (ME1 and ME2) or for the commercial topical formulation (Exoderil)

## CONCLUSION

Our results showed significant naftifine permeation enhancement by a microemulsion formulation comprising oleic acid, Kolliphor RH40, Transcutol, and water when compared with its conventional topical formulation. ATR-FTIR spectra revealed that microemulsions increased the fluidity of the stratum corneum lipid bilayers. Drug-loaded microemulsions showed superior antifungal activity against two *Candida* species. In conclusion, this study demonstrated that a microemulsion formulation of naftifine could be a potential alternative to the conventional formulation of the drug.

## ACKNOWLEDGEMENTS

This work was supported by the Scientific Research Projects Coordination Unit of İstanbul University (Project number NP-512 and BYP-2017-26514).

*Conflict of Interest: No conflict of interest was declared by the authors.*

## REFERENCES

- Gupta AK, Ryder JE, Cooper EA. Naftifine: A Review. *J Cutan Med Surg.* 2008;12:51-58.
- Bondaryk M, Kurzatkowski W, Staniszewska M. Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development. *Postep Derm Alergol.* 2013;30:293-301.
- Güngör S, Erdal MS, Aksu B. New Formulation Strategies in Topical Antifungal Therapy. *Journal of Cosmetics Dermatological Sciences and Applications.* 2013;3:56-65.
- Sintov AC, Shapiro I. New microemulsion vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo. *J Control Release.* 2004;95:173-183.
- Teichmann A, Heuschkel S, Jacobi U, Presse G, Neubert RH, Sterry W, Ladermann J. Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amorphous cream. *Eur J Pharm Biopharm.* 2007;67:699-706.
- Baroli B, López-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Méndez J. Microemulsions for topical delivery of 8-methoxsalen. *J Control Release.* 2000;69:209-218.
- Zhao JH, Ji L, Wang H, Chen ZQ, Zhang YT, Liu Y, Feng NP. Microemulsion-based novel transdermal delivery system of tetramethylpyrazine: preparation and evaluation in vitro and in vivo. *Int J Nanomedicine.* 2011;6:1611-1619.
- Coneac G, Vlaia V, Olariu I, Muñoz AM, Anghel DF, Ilie C, Popoiu C, Lupuleasa D, Vlaia L. Development and evaluation of new microemulsion-based hydrogel formulations for topical delivery of fluconazole. *AAPS PharmSciTech.* 2015;16:889-904.
- Sintov AC. Transdermal delivery of curcumin via microemulsion. *Int J Pharm.* 2015;481:97-103.
- Lopes LB. Overcoming the cutaneous barrier with microemulsions. *Pharmaceutics.* 2014;6:52-77.
- Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: a novel approach to enhanced drug delivery. *Recent Pat Drug Deliv Formul.* 2008;2:238-257.
- Erdal MS, Özhan G, Mat MC, Özsoy Y, Güngör S. Colloidal nanocarriers for the enhanced cutaneous delivery of naftifine: characterization studies and in vitro and in vivo evaluations. *Int J Nanomedicine.* 2016;11:1027-1037.
- Bommannan D, Potts RO, Guy RH. Examination of stratum corneum barrier function in vivo by infrared spectroscopy. *J Invest Dermatol.* 1990;95:403-408.
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
- CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts 4<sup>th</sup> ed. CLSI standard M27. Clinical and Laboratory Standards Institute; 2017.
- Chrysanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. *J Clin Microbiol.* 2002;40:3841-3844.

17. Ge S, Lin Y, Lu H, Li Q, He J, Chen B, Wu C, Xu Y. Percutaneous delivery of econazole using microemulsion as vehicle: Formulation, evaluation and vesicle-skin interaction. *Int J Pharm.* 2014;465:120-131.
18. Hosmer J, Reed R, Bentley MV, Nornoo A, Lopes LB. Microemulsions containing medium-chain glycerides as transdermal delivery systems for hydrophilic and hydrophobic drugs. *AAPS PharmSciTech.* 2009;10:589-596.
19. Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of ketoprofen using microemulsions. *Int J Pharm.* 2001;228:161-170.
20. Panapisal V, Charoensri S, Tantituvanont A. Formulation of microemulsion systems for dermal delivery of silymarin. *AAPS PharmSciTech.* 2012;13:389-399.
21. Kajbafvala A, Salabat A, Salimi A. Formulation, characterization, and *in vitro/ex vivo* evaluation of quercetin-loaded microemulsion for topical application. *Pharm Dev Technol.* 2018;23:741-750.
22. Butani D, Yewale C, Misra A. Amphotericin B topical microemulsion: formulation, characterization and evaluation. *Colloids Surf B Biointerfaces.* 2014;116:351-358.
23. Lin YH, Tsai MJ, Fang YP, Fu YS, Hung YB, Wu PC. Microemulsion formulation design and evaluation for hydrophobic compound: Catechin topical application. *Colloids Surf B Biointerfaces.* 2018;161:121-128.
24. Schwarz JC, Pagitsch E, Valenta C. Comparison of ATR-FTIR spectra of porcine vaginal and buccal mucosa with ear skin and penetration analysis of drug and vehicle components into pig ear. *Eur J Pharm Sci.* 2013;50:595-600.
25. Uzqueda M, Martín C, Zornoza A, Sánchez M, Martínez-Ohárriz MC, Vélaz I. Characterization of complexes between naftifine and cyclodextrins in solution and in the solid state. *Pharm Res.* 2006;23:980-988.
26. Raju YP, N H, Chowdary VH, Nair RS, Basha DJ, N T. *In vitro* assessment of non-irritant microemulsified voriconazole hydrogel system. *Artif Cells Nanomed Biotechnol.* 2017;45:1539-1547.
27. Jadhav KR, Shetye SL, Kadam VJ. Design and Evaluation of Microemulsion Based Drug Delivery System. *Int J Adv Pharm.* 2010;1:156-166.
28. El-Hadidy GN, Ibrahim HK, Mohamed MI, El-Milligi MF. Microemulsions as vehicles for topical administration of voriconazole: formulation and *in vitro* evaluation. *Drug Dev Ind Pharm.* 2012;38:64-72.
29. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. *Eur J Cancer.* 2001;37:1590-1598.
30. Khattab A, Ismail S. Formulation and evaluation of oxiconazole mucoadhesive nanoemulsion based gel for treatment of fungal vaginal infection. *Int J Pharmacy and Pharm Sci.* 2016;8:33-40.
31. Abd-Elsalam WH, El-Zahaby SA, Al-Mahallawi AM. Formulation and *in vivo* assessment of terconazole-loaded polymeric mixed micelles enriched with Cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery. *Drug Deliv.* 2018;25:484-492.